Physical endurance extremely-low-frequency electromagnetic therapy unit MagnaCore

muscle recoverytransportable

Overview
MagnaCore is an electro‑magnetic stimulation (EMS) medical device designed to induce supramaximal muscle contractions for muscle hypertrophy, functional rehabilitation and adjunctive fat reduction. It is US FDA‑cleared for safety and clinical use.

Mechanism of action
MagnaCore delivers focused high‑intensity electromagnetic pulses that pass through skin and subcutaneous tissue to depolarize intramuscular motor nerves. This produces powerful involuntary contractions that exceed voluntary exercise intensity, driving structural and metabolic adaptations.

Indications & targeted outcomes

• Muscle building: Stimulates deep muscle fibers to increase thickness and definition.
• Athletic performance: Improves strength, endurance and recovery when integrated into training plans.
• Rehabilitation: Facilitates neuromuscular re‑education, reduces atrophy and supports functional recovery.
• Adjunct fat reduction: Secondary effect via increased energy demand, lipolysis and possible adipocyte apoptosis with repeated sessions.

Key benefits

• Time‑efficient: Typical sessions 20–30 minutes; >20,000 supramaximal contractions per 30‑minute treatment.
• Customizable protocols: Adjustable frequency, intensity and pre‑programmed protocols for clinical objectives.
• Deep penetration: Targets fibers up to 7 cm below the skin surface.
• Non‑invasive: No incisions or implants; tolerated by most patients.

Technical specifications

• Technology: High‑intensity electro‑magnetic stimulation (EMS).
• Probes: Dual rear probes with large surface area for broad muscle engagement.
• Frequency range: 1–150 Hz (1–10 Hz twitch; 20–30 Hz tetany onset; 50–150 Hz sustained tetany for supramaximal contractions).
• Session duration: 20–30 minutes (device induces >20,000 supramaximal contractions in 30 minutes).
• Controls: Adjustable intensity/duration and user‑friendly interface with pre‑programmed protocols.

Treatment protocol & clinical results

• Protocol: Typical course 4–6 sessions over 2–3 weeks for initial outcomes; maintenance schedules vary.
• Clinical outcomes: Mean reported increases in muscle mass ~15–20% and fat layer reduction in treated areas ~15–19% after 4–6 sessions (secondary to muscle activity).

Physiology & histology

• Muscle hypertrophy: Enlargement of muscle fibers via increased contractile protein synthesis.
• Satellite cell activation: Recruitment and fusion of muscle stem cells supports long‑term growth potential.
• Vascular and mitochondrial adaptations: Angiogenesis and mitochondrial biogenesis support metabolic and endurance improvements.

Safety & regulatory
MagnaCore is designed for clinical use with programmable safety limits. It is US FDA‑cleared; device use should follow manufacturer guidelines and contra‑indications screening (e.g., implanted electronic devices, pregnancy).